Terbinafine

Journal of Drug Evaluation

Volumn 2, Issue 5, 2004, Pages 133-155

  Humphreys, Frances ^a  

^a WARWICK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLYLAMINE DERIVATIVE; AMOROLFINE; BIFONAZOLE; CIMETIDINE; CLOTRIMAZOLE; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 2D6; DESIPRAMINE; GRISEOFULVIN; ITRACONAZOLE; MICONAZOLE; NAFTIFINE; NORTRIPTYLINE; PLACEBO; POLYENE; PYRROLE DERIVATIVE; RIFAMPICIN; TERBINAFINE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; AGE; ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BREAKTHROUGH BLEEDING; BREAST FEEDING; BRONCHOSPASM; CANDIDIASIS; CELLULITIS; CHROMOMYCOSIS; CLINICAL FEATURE; CLINICAL TRIAL; COCHRANE LIBRARY; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; CREAM; CULTURE MEDIUM; DEPRESSION; DERMATOMYCOSIS; DERMATOPHYTE; DIAGNOSTIC PROCEDURE; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERANCE; DRUG URINE LEVEL; DYSPEPSIA; EMULSION; EPIDERMOLYSIS; ERYTHEMA MULTIFORME; ERYTHRODERMA; FATIGUE; FLATULENCE; GEL; GENDER; GROWTH INHIBITION; HAIR LOSS; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INFECTION RISK; INTESTINE OBSTRUCTION; JAUNDICE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LD 50; LEG EDEMA; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FAILURE; MALAISE; MENSTRUATION DISORDER; META ANALYSIS; MICROSCOPY; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MORBIDITY; MOTOR DYSFUNCTION; MYALGIA; MYCOSIS; NAIL INFECTION; NAUSEA; NONHUMAN; ONYCHOMYCOSIS; PATHOGENESIS; PHOTOSENSITIVITY; PREGNANCY; PREVALENCE; PRURITUS; PULSATILE DRUG RELEASE; QUALITY OF LIFE; RACE DIFFERENCE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCAR FORMATION; SEBORRHEIC DERMATITIS; SKIN BURNING SENSATION; STOMATITIS; STROKE; STRUCTURE ACTIVITY RELATION; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TASTE DISORDER; TINEA CAPITIS; TINEA CORPORIS; TINEA CRURIS; TINEA PEDIS; TINEA VERSICOLOR; TREATMENT FAILURE; TREATMENT OUTCOME; URTICARIA; VOMITING; XEROSTOMIA;

EID: 18644366940     PISSN: 14791137     EISSN: None     Source Type: Journal    
DOI: 10.1080/14791130500070064     Document Type: Review

References (123)

1. Roberts DT. Prevalence of dematophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatology 1992;126(Suppl): 23-7
2. Jones TC, Villars VV. Terbinafine. In Ryley JF, ed. Handbook of Experimental Pharmacology. Chemotherapy of Fungal Diseases, volume 96. Springer-Verlag, 1990:483-503
3. Stütz A. Allylamine derivatives - a new class of active substances in antifungal chemotherapy. Angew Chem Int Ed Eng 1987;26:320-8
4. Brautigam M, Weidinger G. Clinical experience with naftifine. In Rippon JW, Frontling R, eds. Cutaneous Anti-fungal Agents. Clinical Dermatology. New York: Marcel Dekker, 1993:99-115
5. Ryder NS. The mechanism of action of terbinafine. Clin Experimental Dermatology 1989;14:98-100
6. Petrany G, Ryder NS, Stutz A. Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science 1984;224:1239-41
7. Ciftci E, Guriz H, Aysev AD. Mupiricin vs terbinafine in impetigo. Indian J Pediatr 2002;69:679-82
8. Lee WS, Chen RJ, Wang YJ, et al. In vitro and in vivo studies of the anticancer action of terbinafine in human cancer cell lines; GO/G1 p53-associated cell cycle arrest. Int J Cancer 2003;106:125-37
9. Hill S, Thomas R, Smith SG, et al. An investigation of the pharmacokinetics of topical terbinafine (Lamisil) 1% cream. Br J Dermatology 1992;127:396-400
10. Jensen JC. Clinical pharmacokinetics of terbinafine (Lamisil). Clin Experimental Dermatology 1989;14:110-3
11. Faergemann J, Zehender H, Jones T, et al. Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. Acta Derm Venereol 1990;71:322-6
12. Finlay AY, Lever L, Thomas R, et al. Nail matrix kinetics of oral terbinafine in onychomycosis and normal nails. J Dermatol Treatment 1990;1(Suppl):51-3
13. Ryder NS, Dupont M-C. Inhibition of squalene epoxidase by allylamine antimycotic compounds: a comparitive study of the fungal and mammalian enzymes. Biochemical J 1985;230:765-70
14. Schuster I, Ryder NS. Allylamines - mode and selectivity of action compared to azole antifungals and biological fate in mammalian organisms. J Dermatol Treat 1990;1(Suppl):7-9
15. Van Der Kuy PH, Van Den Heuvel HA, Kempen RW, et al. Pharmacokinetic interaction between nortriptyline and terbinafine. Annals Pharmacotherapy 2002;36:1712-4
16. Madani S, Barilla D, Cramer J, et al. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P4502D6 (CYP2D6) extensive metabolisers. J Clin Pharmacol 2002;42:1211-8
17. Jensen JC. Pharmacokinetics of Lamisil in humans. J Dermatol Treatment 1990;1(Suppl);15-18
18. Back DJ, Tjia JF, Abel SM. Azoles, allylamines and drug metabolism. Br J Dermatology 1992;126(Suppl):14-18
19. Jensen P, Lehne G, Fauchald P, et al. Effect of oral terbinafine treatment on ciclosporin pharmacokinetics in organ transplant recipients with dermatophyte nail infection. Acta Derm Venereol 1996;76:280-1
20. Summerbell RC, Kane J, Krajden S. Onychomycosis, tinea pedis and tinea manuum caused by non-dermatophytic filamentous fungi. Mycoses 1989;32:609-19.
21. English MP, Gibson MD. Studies in the epidemiology of tinea pedis. Br Med J 1959;15(5135):1442-6
22. English MP, Wethered RR, Duncan EHL. Studies in the epidemiology of tinea pedis. VIII. Fungal infection in a long stay hospital. Br Med J 1967;3(558):136-139.
23. Gentles JC, Holmes JG. Foot ringworm in coal-miners. Br J Industrial Med 1957;14:22-9
24. Gentles JC, Evans EG. Foot infections in swimming baths. Br Med J 1973;3(5874):260-262.
25. Howell SA, Clayton YM, Phan QG, et al. Tinea pedis: the relationship between symptoms, organisms and host characteristics. Microbiol Ecology Health Dis 1988;1:131-5
26. Hay RJ, Clayton YM, de Silva N, et al. Tinea capitis in south-east London - a new pattern of infection with public health implications. Br J Dermatology 1996;135: 955-8
27. Sharma V, Hall JC, Knapp JF, et al. Scalp colonisation by Trichophyton tonsurans in an urban pediatric clinic. Arch Dermatology 1988;124:1511-3
28. Dupuy A. Risk factors for erysipelas of the leg (cellulitis): case control study. Br Med J 1999;318:1591-4
29. Fuller LC, Child FC, Midgeley G, et al. Practical method for the diagnosis of scalp ringworm; validation of the toothbrush technique. J Europ Acad Derm Venereol 1997;9(Suppl):209
30. Crawford F, Hart R, Bell-Syer F, et al. Topical treatment for fungal infections of the skin and nails of the foot (Cochrane Review). The Cochrane Library 2002: 4
31. Berman B, Ellis C, Leyden J, et al. Efficacy of a 1-week, twice-daily regimen of terbinafine 1% cream in the treatment of interdigital tinea pedis. J Am Acad Dermatol 1992;26:956-60
32. Evans EGV, James IGV, Joshipura RC. Two week treatment of tinea pedis with terbinafine: a placebo controlled study. J Dermatological Treatment 1991;2:95-7
33. Savin RC. Treatment of chronic tinea pedis (athletes foot type) with topical terbinafine. J Am Acad Dermatology 1990; 23:786-9
34. Savin RC, Atton AV, Bergstresser PR, et al. Efficacy of terbinafine 1% cream in the treatment of moccasin type tinea pedis: Results of placebo controlled multicentre trials. J Am Acad Dermatology 1994;30:663-7
35. Smith EB, Noppakun N, Newton RC. A clinical trial of topical terbinafine (a new allylamine antifungal) in the treatment of tinea pedis. J Am Acad Dermatology 1990;23:790-4
36. Ablon G, Rosen T, Spedale J. Comparative efficacy of naftifine, oxiconazole and terbinafine in short term treatment of tinea pedis. Int J Dermatology 1996;35:591-3
37. Bergstresser PR, Elewski B, Hanifin J, et al. Topical terbinafine and clotrimazole in interdigital tinaea pedis: a multicentre comparison of cure and relapse rates with 1 and 4 week treatment regimens. J Am Acad Dermatology 1993;28:648-51
38. Evans EGV, Dodman B, Williamson DM, et al. Comparison of terbinafine and clotrimazole in treating tinea pedis. Br Med J 1993;307:645-7
39. Sanchez-Carazo JL, Fuente C, Oliver V, et al. Estudio comparitivo de terbinafine vs. bifonazol crema al 1% en aplicacion unica diaria en tina pedis. Actas Dermo-Sifiliograficas 1994;85:388-94
40. Vermeer BJ, Staats CCG, Van Houweilingen JC. Terbinafine versus miconazol bij patienten met tinea pedis. Ned Tijdschr Geneeskd 1996;140:1605-8
41. Korting HC, Tietz HJ, Braütigam M, et al. One week terbinafine 1% cream (Lamisil) once daily is effective in the treatment of interdigital tinea pedis: a vehicle controlled study. Med Mycology 2001;39:335-40
42. Patel A, Brookman D, Bullen MU, et al. Topical treatment of interdigital tinea pedis: terbinafine compared with clotrimazole. Aust J Dermatology 1999;40:197-200
43. Leenutaphong V, Tangwiwat S, Muanprasat C, et al. Double-blind study of the efficacy of 1 week topical terbinafine cream compared to 4 weeks miconazole cream in patients with tinea pedis. J Med Assoc Thai 1999;82:1006-9
44. Getting rid of athlete's foot. Drugs Ther Bulletin 2002;40:53-4
45. Athlete's foot. Treatment Notes. Consumers association, 2002:23
46. Villars V, Jones TC. Clinical efficacy and tolerability of terbinafine (Lamisil) - a new topical and systemic fungicidal drug for treatment of dermatomycosis. Clin Exp Dermatology 1989;14:124-7
47. Jones TC. Treatment of dermatomycosis with topically applied allylamines: naftifine and terbinafine. J Dermatological Treatment 1990;1(Suppl):29-32
48. Kagawa S. Clinical efficacy of terbinafine in 629 Japanese patients with dermatomycosis. Clin Exp Dermatology 1989;14:114-5
49. Zaias N, Berman B, Cordero C, et al. Efficacy of a 1-week, once-daily regimen of terbinafine 1% cream in the treament of tinea cruris and tinea corporis. J Am Acad Dermatology 1993;29:646-8
50. Budimulja U, Bramono K, Urip KS, et al. Once daily treatment with terbinafine 1% cream (Lamisil) for one week is effective in the treatment of tinea corporis and cruris. A placebo-controlled study. Mycoses 2001;44:300-6
51. Evans EGV, Seaman RAJ, James IGV. Short-duration therapy with terbinafine 1% cream in dermatophyte skin infections. Br J Dermatology 1994;130:83-7
52. Mieth H. In vitro and in vivo activities of terbinafine. In Rippon JW, Frontling RA, eds. Cutaneous Antifungal Agents in Clinical Dermatology. New York: Marcel Dekker, 1993:137-49
53. Aste N, Pau M, Pinna AL, et al. Clinical efficacy and tolerability of terbinafine in patients with Pityriasis versicolor. Mycoses 1991;34:353-7
54. Faergemann J, Hersle K, Nordin P. Pityriasis versicolor: clinical experience with Lamisil cream and Lamisil Dermgel. Dermatology 1997;194(Suppl):19-21
55. Faergemann J, Jones TC, Hettler O, et al. Pityrosporum ovale (Malassezia furfur) as the causative agent of seborrhoeic dermatitis: new treatment options. Br J Dermatology 1996;134(Suppl):12-15
56. Bell-Syer SEM, Hart R, Crawford F, et al. Oral treatments for fungal infections of the skin of the foot (Cochrane Review). The Cochrane Library 2002;4
57. Savin RC, Zaias N. Treatment of chronic moccasin-type tinea pedis with terbinafine: a double-blind placebo-controlled trial. J Am Acad Dermatology 1990;23: 804-7
58. Savin RC. Terbinafine (Lamisil) versus griseofulvin in moccasin-type tinea pedis. J Dermatol Treatment 1990;1(Suppl):43-6
59. Widyanto, Budimulja U, Kuswadji, et al. A randomized, double-blind comparative study of terbinafine versus griseofulvin in tinea pedis. In: Shuster S, Jafary MH, eds. Terbinafine in the Treatment of Superficial Fungal Infections. Asia-Pacific Symposium on Lamisil. London: Royal Society of Medicine Services, 1993: 21-4
60. De Keyser P, De Backer M, Massart DL, et al. Two-week oral treatment for tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double-blind multicentre study. Br J Dermatology 1994;130(Suppl):22-5
61. Hay RJ, McGregor JM, White J, et al. A comparison of 2 weeks terbinafine 250mg/day with 4 weeks of itraconazole 100 mg/day in plantar-type tinea pedis. Br J Dermatology 1995;132:604-8
62. Kim JH, Yoon KB. Single-blind randomized study of terbinafine versus itraconazole in tinea pedis (two weeks vs four weeks). In: Shuster S, Jafary MH, eds. Terbinafine in the Treatment of Superficial Fungal Infections. Asia-Pacific symposium on Lamisil. London: Royal Society of Medicine Services, 1993:17-20
63. Voravutinon V. Double-blind comparative study of the efficacy and tolerability of terbinafine with itraconazole in patients with tinea pedis. In: Shuster S, Jafary MH, eds. Terbinafine in the Treatment of Superficial Fungal Infections. Asia-Pacific symposium on Lamisil. London: Royal Society of Medicine Services, 1993:11-16
64. Hay RJ, Logan RA, Moore MK, et al. A comparative study of terbinafine versus griseofulvin in 'dry-type' dermatophyte infections. J Am Acad Dermatology 1991;24:243-6
65. Tausch I, Decroix J, Gwiezdzinski Z, et al. Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus. Int J Dermatology 1998;37:128-44
66. Barnetson RSC, Marley J, Bullen M, et al. Comparison of one week of oral terbinafine (250mg/day) with 4 weeks of treatment with clotrimazole 1% cream in interdigital tinea pedis. Br J Dermatology 1998;139:675-8
67. Frieden IJ, Howard R. Tinea capitis: Epidemiology, diagnosis, treatment and control. J Am Acad Dermatology 1994;31:542-6
68. Babel DE, Baughman A. Evaluation of the adult carrier state in juvenile tinea capitis caused by Trichophyton tonsurans. J Am Acad Dermatology 1989;21:1209-12
69. Haroon TS, Hussain I, Mahmood I, et al. An open clinical pilot study of the efficacy and safety of oral terbinafine in dry non-inflammatory tinea capitis. Br J Dermatology 1992;126(Suppl):47-50
70. Haroon TS, Hussain T, Aman S, et al. A randomized double-blind comparitive study of terbinafine and griseofulvin in tinea capitis. J Dermatol Treatment 1995;6;167-9
71. Fuller LC, Smith CH, Cerio R, et al. A randomized comparison of 4 weeks of terbinafine vs 8 weeks of griseofulvin for the treatment of tinea capitis. Br J Dermatol 2001;144:321-7
72. Jahangir M, Hussain I, Hasan M, et al. A double-blind randomized, comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis. Br J Dermatology 1998;139:672-4
73. Hamm H, Schwinn A, Braütigam M, et al. Short duration treatment with terbinafine for tinea capitis caused by Trichophyton or Microsporum species. Br J Dermatology 1999;140:480-2
74. Fuller LC, Child FJ, Midgeley G, et al. Diagnosis and management of scalp ringworm. Br Med J 2003;326:539-41
75. Jones TC. Overview of the use of terbinafine (Lamisil) in children. Br J Dermatology 1995;132:683-9
76. Baudraz-Rosselet F, Monod M, Jaccoud S, et al. Efficacy of terbinafine treatment of tinea capitis varies according to the dermatophyte species. Br J Dermatology 1996;135:1011
77. Villars V, Jones TC. Present status of the efficacy and tolerability of terbinafine (Lamisil) used systemically in the treatment of dermatomycosis of skin and nails. J Dermatological Treatment 1990;1(Suppl):33-8
78. Voravutinon V. Oral treatment of tinea corporis and cruris with terbinafine and griseofulvin: a randomized double blind comparitive study. J Med Assoc Thai 1993;76:388-93
79. Farag A, Taha M, Halim S. One week therapy with oral terbinafine in cases of tinea cruris/corporis. Br J Dermatology 1994;131:684-6
80. Harris J. Do crinkly toenails really matter? Br Med J 1999-319:1197
81. Stone N, Dawber R. Toenail onychomycosis can cause serious problems. Br Med J 2000;320:448
82. Crawford F, Young P, Godfrey C, et al. Oral treatments for fungal infections of the toenails. Protocol for a Cochrane Review. The Cochrane Library 2002;4
83. Goodfield MJD. Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. Br J Dermatology 1992;126(Suppl):33-5
84. Drake LA, Shere NH, Arlette JP, et al. Oral terbinafine in the treatment of toenail onychomycosis. J Am Acad Dermatology 1997;37:740-5
85. Svejfaard EL, Brandrup F, Kragballe K, et al. Oral terbinafine in toenail dermatophytosis. Acta Derm Venereol 1997;77:66-9
86. Hofmann H, Brautigam M, Weidinger G, et al. Treatment of toenail onychomycosis. Arch Dermatol 1995;131:919-22
87. De Backer M, De Keyser P, De Vroey C, et al. A 12 week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day versus itraconazole 200 mg/day - a double-blind comparitive trial. Br J Dermatology 1996;134(Suppl):16-17
88. Brautigam M, Nolting S, Schopf RE, et al. Randomized double-blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Br Med J 1995;311:919-22
89. Evans EGV, Sigurgeirsson B. Double-blind, randomized study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. Br Med J 1999;318:1031-5
90. Sigurgeirsson B, Olafsson JH, Steinsson JP, et al. Long-term effectiveness of treatment with terbinafine versus itraconazole in onychomycosis. Arch Dermatol 2002;138:353-7
91. Roberts DT. Oral therapeutic agents in fungal nail disease. J Am Acad Dermatology 1994;31:578-81
92. Denning DW, Evans EGV, Kibbler CC, et al. Fungal nail disease: a guide to good practice (report of a Working Group of the British Society for Medical Mycology). Br Med J 1995;311:1277-81
93. Crawford F, Young P, Godfrey C, et al. Oral treatments for toenail onychomycosis. Arch Dermatology 2002;138:811-6
94. Haugh M, Helon S, Boissel JP, et al. Terbinafine in fungal infections of the nails: a meta-analysis of randomized clinical trials. Br J Dermatology 2002;147:118-21
95. Roberts DT, Talyor WD, Boyle J. Guidelines for treatment of onychomycosis. Br J Dermatology 2003;148:402-10
96. Alpsoy E, Yilmaz E, Basaran E. Intermittent therapy with terbinafine for dermatophyte toe onychomycosis: A new approach. J Dermatology 1996;23:259-62
97. Tosti A, Piraccini BM, Stinchi C, et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatology 1996;34:595-600
98. Van der Schroeff JG, Cirkel PKS, Crijins MB, et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatology 1992; 126(Suppl):36-9
99. Olafsson JH, Sigurgeirsson B, Baran R. Combination therapy for onychomycosis. Br J Dermatology 2003; 149(Suppl):15-18
100. Gianni C, Cerri A, Crosti C. Unusual clinical features of fingernail infection by Fusarium oxysporum. Mycoses 1997;40:455-9
101. Budimulja U, Kuswadji K, Bramano S, et al. A double-blind, randomized, stratified controlled study of the treatment of tinea imbricata with oral terbinafine or itraconazole. Br J Dermatology 1994;130(Suppl):29-31
102. Wingfield AB, Fernandez-Obregon AC, Wignall FS, et al. Treatment of tinea imbricata: a randomized clinical trial using griseofulvin, terbinafine, itraconazole and fluconazole. Br J Dermatology 2004;150:119-126
103. Gip L. Black piedra: the first case treated with terbinafine (Lamisil). Br J Dermatology 1994;130(Suppl):26-8
104. Hull PR, Vismet HF. Treatment of cutaneous sporotrichosis with terbinafine. Br J Dermatology 1992; 126(Suppl):51-5
105. Schiraldi GF, Lo Cicero S, Colombo MD, et al. Refractory pulmonary aspergillosis: compassionate trial with terbinafine. Br J Dermatology 1996;134(Suppl): 25-9
106. Esterre P, Inzan Ck, Ramarcel ER, et al. Treatment of chromomycosis with terbinafine: preliminary results of an open pilot study. Br J Dermatology 1996;134(Suppl): 33-6
107. Villars VV, Jones TC. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br J Dermatology 1996;126(Suppl):61-9
108. Nandwani R, Parnell A, Youle M, et al. Use of terbinafine in HIV-positive subjects: pilot studies in onychomycosis and oral candidiasis. Br J Dermatology 1996; 134(Suppl):22-4
109. Herranz P, Garcaia J, De Lucas R, et al. Toenail onychomycosis in patints with acquired immune deficiency syndrome; treatment with terbinafine. Br J Dermatology 2004;150;414-20
110. Smith S, Houpt K, Rich P, et al. Short duration oral terbinafine for the treatment of tinea pedis in HIV-positive patients. Cutis 2001;68(Suppl):30-9
111. Rich P, Houpt K, LaMarca A, et al. Safety and efficacy of short duration oral terbinafine for the treatment of tinea corporis or tinea cruris in subjects with HIV infection or diabetes. Cutis 2001;68(Suppl):15-22
112. Cribier BJ, Bakshi R. Terbinafine in the treatment of onychomycosis: a review of its efficacy in high-risk populations and in patients with nondermatophyte infections. Br J Dermatology 2004;150:414-20
113. Committee on Safety of Medicines. Personal communication, 2004
114. Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine. Arch Dermatol 1997;133:1213-9
115. O'Sullivan DP, Needham CA, Bangs A, et al. Post marketing surveillance of oral terbinafine in the UK: report of a large cohort study Br J Clin Pharmacol 1996;42:559-65
116. Roberts DT. Systemic antifungals as a cause of liver damage. Prescribers J 1998;38:190-4
117. Lovell MO, Speeg KV, Havranek RD. Histological changes resembling acute rejection in a liver transplant recipient treated with terbinafine. Human Pathology 2003;34:187-9
118. Humphrey KM, Court MJ, Haycocks A. A retrospective cost effectiveness analysis of the treatment of onychomycosis in general practice. Br J Dermatology 1998; 139:660-4
119. Jensen R, Redekop WK, Rutten FH. Cost effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis. Pharmacoeconomics 2001;19:401-10
120. Marchetti A, Piech KT, McGhan WF, et al. Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model. Clin Ther 1996;18:757-7
121. Bootman JL. Cost-effectiveness of two new treatments for onychomycosis; an analysis of two comparative clinical trials. J Am Acad Dermatology 1998;38:569-72
122. Van Doorslar EKA, Tormans G, Gupta AK, et al. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany. Pharmacology Treatment 1996;193:239-44
123. Gupta AK. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte oychomycosis of the toenails Pharmacoeconomics 1998;13:243-56